Education
About Us
Working with TipRanks
Follow Us
Benatti Luca Insider Profile
11 Followers
Benatti Luca, Director at Intercept Pharma, holds 89.18K shares in Quince Therapeutics (Ticker: QNCX), holds 33.60K shares in Intercept Pharma (Ticker: ICPT). Most recently, Benatti Luca Sold ― shares of Quince Therapeutics on Dec 29, 2025 for an estimated value of $173.50K.
Profitable Transactions
2 out of 3 Profitable Transactions
Average Return
+12.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Benatti Luca holds in companies
Most Profitable Insider Trade
Stock:
Intercept Pharma
(ICPT)
(ICPT)
Rating:Informative Buy
Date:Dec 15, 2014 - Dec 15, 2015
Return:+21.80%
The most profitable trade made by Benatti Luca
Benatti Luca's Trading History
Intercept Pharma
May 25, 2023
―
Uninformative Buy
―
$638.36K
Quince Therapeutics
Dec 29, 2025
Director
Informative Sell
173.50K
$15.16K
List of latest transactions for each holding click on a transaction to see Benatti Luca's performance on stock
You May Also Like
Benatti Luca insider profile FAQ
What is the percentage of profitable transactions made by Benatti Luca?
The percentage of profitable transactions made by Benatti Luca is 67%.
What is the average return per transaction made by Benatti Luca?
The average return per transaction made by Benatti Luca is 12.80%.
What stocks does Benatti Luca hold?
Benatti Luca holds: ICPT, QNCX stocks.
What was Benatti Luca’s latest transaction?
Benatti Luca latest transaction was an Informative Sell of $173.50K.
What was Benatti Luca's most profitable transaction?
Benatti Luca’s most profitable transaction was an Informative Buy of ICPT stock on December 15, 2014. The return on the trade was 21.80%.
What is Benatti Luca's role in Intercept Pharma?
Benatti Luca's role in Intercept Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.